Month: March 2025

ONP-002 Advances Toward Phase IIa Concussion Trial with Strengthened Financial Foundation and Industry Momentum SARASOTA, Fla., March 27, 2025 (GLOBE NEWSWIRE) — Oragenics, Inc. (NYSE American: OGEN), a biotechnology company focused on developing novel intranasal therapies for brain-related conditions, today provided shareholders with an update on its strategic and financial progress for the first quarter of 2025. The Company has made meaningful advancements across regulatory, clinical, financial, and partnership initiatives, further positioning its lead therapeutic candidate, ONP-002, as a first-in-class solution for treating concussion. “We believe ONP-002 is one of the most undervalued clinical assets in biotechnology today,” said Janet Huffman, Interim CEO of Oragenics. “With strong preclinical validation and clinical safety...

HOUSTON, March 27, 2025 (GLOBE NEWSWIRE) — FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that its 2025 Annual Meeting of Stockholders will take place on June 12, 2025, at 11 a.m. CDT, exclusively through a virtual format. The record date for determination of stockholders entitled to vote at the annual meeting is April 14, 2025. About FibroBiologicsBased in Houston, FibroBiologics is a clinical-stage biotechnology company developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds 160+ US and internationally...

The SSI Mantra 3 Surgical Robotic System enabled a seamless connection from SS Innovations headquarters in Gurugram, India to Aster CMI Hospital in Bengaluru, India covering a distance over 2,000 km. The SSi Mantra, India’s first CDSCO*-approved surgical robotic system for telesurgery, brings precision and accessibility to complex surgical procedures.FORT LAUDERDALE, Fla., March 27, 2025 (GLOBE NEWSWIRE) — SS Innovations International, Inc. (OTC: SSII) (“SS Innovations” or the “Company”), a developer of innovative robotic surgical technologies dedicated to making world-class robotic surgery affordable for and accessible to a global population, announced that it successfully performed India’s first North-to-South robotic cardiac telesurgery. Made possible by our advanced SSi Mantra 3 Surgical Robotic System, this landmark procedure...

Reinforces potential of nebokitug to become the first approved drug with disease-modifying activity for PSC–a deadly disorder that currently has no effective treatments Treatment in PSC patients with moderate/advanced disease for 48 weeks resulted in continued improvements across key biomarkers of liver injury, inflammation and fibrosis, including ELF score, fibrosis-related ELF score components and PRO-C3 Patients treated with nebokitug for 48 weeks showed a significantly lower number of clinical events compared to matching historical controls and significantly reduced progression of liver stiffness vs historical controls, further derisking the planned PSC Phase 3 clinical trial design Treatment for up to 48 weeks was well-tolerated; Reinforces and expands positive results from 15-week double-blind Phase 2 SPRING trial TEL AVIV,...

-Started Two New Clinical Trials, Collaborating with MD Anderson and The Netherlands Cancer Institute for Treatment of Ovarian and Colorectal Cancer- -Received Exclusive Patent License Agreement with the NIH on LB-100’s Potential in Enhancing Cancer Immunotherapies- -Two Breakthrough Publications in Medical Journals, EMBO and Cancer Discovery,Supporting LIXTE’s Clinical Trial Program- PASADENA, Calif, March 27, 2025 (GLOBE NEWSWIRE) — LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical-stage pharmaceutical company developing a new class of cancer therapy to enhance chemotherapy and immunotherapy, today provided an update on its recent activities. “Continued progress has been made in collaborative clinical studies with two global pharmaceutical companies for our lead proprietary...